JPRN-jRCT2073210080招募中1 期
Phase I / II Clinical Trial of GAIA-102 for advanced and relapse NSCLC
Okamoto Isamu0 个研究点目标入组 38 人开始时间: 2021年10月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients who have been confirmed to have NSCLC by histological or cytological examination
- •(2) Patients with ECOG performance status (PS) 0-1 at the time of obtaining consent
- •(3) Patients aged 20 years or older at the time of obtaining consent
排除标准
- •(1) Patients with symptomatological cranial nerve system metastasis. If treatment for cranial nerve system metastasis has already been performed and the neurologically recovered state has been maintained for 2 weeks or more before registration, registration is possible.
- •(2) Patients diagnosed with cancerous meningitis
- •(3) Patients who received allogeneic hematopoietic stem cell transplantation
- •(4) Patients with active autoimmune disease
研究者
相似试验
招募中
不适用
Phase I / II Clinical Trial of GAIA-102 for advanced and relapse NSCLCadvanced and relapse NSCLCJPRN-UMIN000046974GAIA BioMedicine Inc.38
招募中
1 期
Phase I clinical trial of GAIA-102 for refractory/relapse neuroblastomas or malignant pediatric solid tumors with lung metastases.refractory/relapse neuroblastoma or pediatric solid tumors with lung metastasesJPRN-jRCT2073220054Kawakubo Naonori36
招募中
2 期
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with tri-weekly docetaxel (D) followed by doxorubicin, 5-fluorouracil, and cyclophosphamide (FEC) or docetaxel with concurrent use of capecitabine (TX) followed by doxorubicin, cyclophosphamide, and capecitabine (CEX) in women with locally advanced triple-negative breast cancerntreated women with triple negative breast cancer (T1c-4NxM0)JPRN-UMIN000018722Japanese Red Cross Society Himeji Hospital84
进行中（未招募）
不适用
A randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastomaEUCTR2011-000900-16-BEZ BRUSSE
进行中（未招募）
2 期
Phase IIa study (doctor-led trial) for the efficacy and safety of SJP-0008 in central retinal artery occlusiocentral retinal artery occlusionJPRN-jRCT2021190013akazawa Toru20